The DOI matches its Crossref record; the references it cites are not checked yet.
Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders
Open accessAbstract
Gene therapy using recombinant adeno‐associated virus (rAAV) vectors to treat blinding retinal dystrophies has become clinical reality. Therapeutically impactful targeting of photoreceptors still relies on subretinal vector delivery, which detaches the retina and harbours substantial risks of collateral damage, often without achieving widespread photoreceptor transduction. Herein, we report the development of novel engineered rAAV vectors that enable efficient targeting of photoreceptors via less invasive intravitreal administration. A unique in vivo selection procedure was performed, where an AAV2‐based peptide‐display library was intravenously administered in mice, followed by isolation of vector DNA from target cells after only 24 h. This stringent selection yielded novel vectors, termed AAV2.GL and AAV2.NN, which mediate widespread and high‐level retinal transduction after intravitreal injection in mice, dogs and non‐human primates. Importantly, both vectors efficiently transduce photoreceptors in human retinal explant cultures. As proof‐of‐concept, intravitreal Cnga3 delivery using AAV2.GL lead to cone‐specific expression of Cnga3 protein and rescued photopic cone responses in the Cnga3 −/− mouse model of achromatopsia. These novel rAAV vectors expand the clinical applicability of gene therapy for blinding human retinal dystrophies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alternatively, it has been observed that capsids with lower stabilities correlate with improved transduction, owning to more efficient uncoating and release of vector genomes [62,63].”
From The AAV2.7m8 capsid packages a higher degree of heterogeneous vector genomes than AAV2 (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, Pavlou and co-workers published the identification of new AAV variants using the same approach.They identified several rAAV variants after inducing a shift in the geometry of the loop 4, which is also involved in the targeting of the capsid by neutralizing antibodies.”
From Risk mitigation of immunogenicity: a key to personalized retinal gene therapy (2021) · cites this paper as [114]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, development of recombinant vectors AAV2.GL and AAV2.NN improve the retinal delivery of a gene therapy product after intravitreal injection.56,66”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [66]
In the citing paper
“Recombinant AAV (rAAV) vectors have been developed to combine desirable tropisms from multiple serotypes,66 or to reduce immune responses or antibody neutralization.29”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [66]
In the citing paper
“They showed that these new variants have the ability to cross barriers, have a lower heparin affinity, have a capsid that is easier to disassemble, and are less sensitive to neutralization [114].”
From Risk mitigation of immunogenicity: a key to personalized retinal gene therapy (2021) · cites this paper as [114]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 72 · Cited by 135
Metadata
- Authors
- Pavlou, M., Schön, C., Occelli, L. M., Rossi, A., Meumann, N., Boyd, R. F., Bartoe, J. T., Siedlecki, J., Gerhardt, M. J., Babutzka, S., Bogedein, J., Wagner, J. E., Priglinger, S. G., Biel, M., Petersen‐Jones, S. M., Büning, H., & Michalakis, S.
- Affiliations
- Center for Integrated Protein Science Munich (DE)
- Michigan State University (US)
- Medizinische Hochschule Hannover (DE)
- Charles River Laboratories (United States) (US)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Büning, Hildegard
- Michalakis, Stylianos
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2021-02-22
- Volume
- 13
- Issue
- 4
- Pages
- e13392-e13392
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC8033523
- OpenAlex
- W3129547287
- Cited by
- 135
- References
- 72
- Citations by year
- 2026: 29 · 2025: 26 · 2024: 26 · 2023: 19 · 2022: 22 · 2021: 13
- FWCI
- 11.25
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Deutsche Forschungsgemeinschaft (SPP2127, MI 1238/4‐1)
- LMU|Center of Integrated Protein Science Munich, Ludwig‐Maximilians‐Universität München
- UoC|Center for Molecular Medicine Cologne, University of Cologne
- Niedersächsisches Ministerium für Wissenschaft und Kultur
- REBIRTH DFG Cluster of Excellence
- Myers‐Dunlap Endowment
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- recombinant adeno-associated virus vectors, AAV capsid engineering, intravitreal gene therapy, retinal dystrophy, CNGA3, achromatopsia, retinal transduction, non-human primates
- MeSH terms
- Dependovirus, Animals, Capsid, Color Vision Defects, Dogs, Genetic Vectors, Retina, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders. https://app.cochat.ai/papers/10.15252/emmm.202013392
- The paper
- Pavlou, M., Schön, C., Occelli, L. M., Rossi, A., Meumann, N., Boyd, R. F., Bartoe, J. T., Siedlecki, J., Gerhardt, M. J., Babutzka, S., Bogedein, J., Wagner, J. E., Priglinger, S. G., Biel, M., Petersen‐Jones, S. M., Büning, H., & Michalakis, S. (2021). Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202013392
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.